期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

STI571治疗C-Kit阳性肿瘤的研究进展 被引量：2

原文传递
导出
摘要 STI571是近年来研制的一种特异的bcr蛳abl激酶抑制剂,由于它能抑制慢性粒细胞白血病(CML)酪氨酸激酶的活性,针对CML的分子异常进行一种靶向治疗,已被欧美等国广泛应用于临床上治疗慢性粒细胞白血病,目前STI571在C蛳Kit阳性肿瘤:肥大细胞增多症、胃肠间质肿瘤、小细胞肺癌、急性髓性白血病中的作用也越来越受到人们的关注。就近年来该方面的研究进展进行综述。
作者 孟利花 马梁明
机构地区 山西医科大学第二医院血液科
出处 《白血病．淋巴瘤》 CAS 2005年第2期127-128,共2页 Journal of Leukemia & Lymphoma
关键词 STI571 C-KIT 白血病 实体瘤
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Mauro M J, Dwyer M, Heinrich M C, et al.STI571:A paradigm of new agents for cancer therapeutics[J]. Journal of Clinical Oncology,2002, 20(1): 525-334.
  • 2Marks D I, Vonderheid E C, Kurz B W, et al.Analysis of p53 and mdm-2 expression in 18 patients with Sezary syndrome [J]. Br J Haematol, 1996, 92(4):890- 899.
  • 3Daley G Q, van Etten R A, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 bcr- abl gene of the Philadelphia chromosome [J]. Science, 1990,247:824.
  • 4Buchduager E, Zimmermann J, Mett H, et al.Inhibition of the Abl protein- tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative[J]. Cancer Res, 1996, 56:1.
  • 5Virginia C B. Stem cell factor and hematopoiesis[J]. Blood, 1997, 15:1345-1364.
  • 6Valverde L K. Expression of c- Kit receptor CD117 in acute leukemia [J]. Ann Hematol,1996, 72(1):11.
  • 7Holcombe, Randall F G, Maib I D, et al. Expression of Kit and platelet-dereverd growth factor rceptors [alpha]abd [beta]in cholangiocarcinoma and case droport of therapy with imatiniv mesylate (STI571) [J]. Lippincott Williams& Wilkins Inc, 2003, 14 (8): 651 -657.
  • 8Bene M C, Bernier M, Casasnovas R O, et al.The reliability and specificity of C-Kit for the diagosis of acute myeloid leukemias and undifferentiated leukemias[J]. Blood, 1998, 92(2): 596-599.
  • 9Scapppini B, Onida F, Kantarjian H M, et al.Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells [J]. Clin Cancer Res, 2001, 7(12):3884-3893.
  • 10Kindler T, Breitenbuecher F, Marx A,et al.Sustaine complete hematologic remission after administration of the tyrosion kinase inhibitor imatinib mesylate in a patient with refractory,secondary AML[J]. Blood, 2003,101(8):2960-2962.

同被引文献26

  • 1姚尔固.白血病的靶向治疗[J].白血病．淋巴瘤,2005,14(1):41-42. 被引量：2
  • 2Look AT. Oncogenic transcription factors in the human acute leukemias[J]. Science, 1997, 278(5): 1059-1064.
  • 3Kelly LM, Gilliland DG. Genetics of myeloid leukemias [J]. Ann Rev Genomics Hum Genet, 2002, 3(9): 179-198.
  • 4Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, consistent chromosomal change in acute promyelocytic leukaemia [J]. Lancet, 1977, 1(2): 549-550.
  • 5de The H, Chomienne C, Lanotte M. The t(15, 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor [alpha] gene to a novel transcribed locus[J]. Nature, 1990, 347(3): 558-561.
  • 6Melnick A, Licht JD. Deconstructing a disease: RAR{alpha}, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia[J]. Blood, 1999, 93(48): 3167-3215.
  • 7Zhang SJ, Ma LY, Huang QH, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia[J]. PNAS, 2008, 105(5): 2076-2081.
  • 8Cunningham I, Gee TS, Reich LM, et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital [J]. Blood, 1989, 73(6): 1116-1122.
  • 9Ribeiro RC, Rego E. Management of APL in enveloping countries: epidemiology, challenges and opportunities for international collaboration[J]. Hematology. 2006, 2006(6): 162-168.
  • 10Tallman MS. Andersen JW, Schiffer CA, et al. All-trans retinnic acid in acute promyeloeytic leukemia: long-term outcome and prognostic factor analysis from the north american intergroup protocol[J]. Blood, 2002, 100(4): 4298-4302.

引证文献2

二级引证文献4

白血病．淋巴瘤
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部